Last reviewed · How we verify
Standard IV administration of vancomycin
At a glance
| Generic name | Standard IV administration of vancomycin |
|---|---|
| Sponsor | The Methodist Hospital Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- IO Vancomycin Spine (PHASE2, PHASE3)
- IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA (NA)
- Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders (PHASE2)
- A Prospective, Randomized Parallel Group Study of the Efficacy of Vancomycin Administered Through Intraarticular Injection Versus Intraosseous Injection Versus Intravenous Infusion in Patients Undergoing Total Knee Arthroplasty (PHASE4)
- IO Vancomycin in TSA (PHASE4)
- TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden (PHASE3)
- Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA) (PHASE1, PHASE2)
- Clinical Decision Support Tool for Vancomycin Dosing in Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: